Figure 4.

Effect of osimertinib and osimertinib plus DHA on the expression of AXL, MET, CDCP1, and GPX4. (A) FaDu and (B) CAL27 cells were treated with 0.5 µM of osimertinib or 0.5 µM of osimertinib plus 20 µM of DHA for three, five and seven days. AXL, MET, CDCP1 and GPX4 mRNA expression were measured using quantitative reverse transcription-PCR. Data were generated from a minimum of three replicates. β-actin was used to normalize gene expression. Data are presented as the means ± standard deviation. The statistical significance was assessed between cell lines treated with osimertinib + DHA and cell lines at basal conditions and treated with osimertinib alone; * two-sided P<0.05. DHA, dihydroartemisinin.